Kiniksa Pharmaceuticals International

KNSA · NASDAQ

$83.17+$3.69 (+4.64%)TodayMarket closed · Oct 20, 7:56 PM ET

Prev close $79.48

KNSA analyst rating

BuyConsensus of 7 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy7
Hold0
Underperform0
Sell0

12-month price target · 10 analysts

Average $98.65 (+18.6% upside)

Low: $87.87
Now: $83.17
High: $113.40

Upgrades and downgrades

The latest rating actions, newest first

KNSA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Goldman Sachs	Jul 30, 2026	Maintains	Buy	$75.00 → $90.00	51%
JP Morgan	Jul 29, 2026	Maintains	Overweight	$72.00 → $107.00	48%
Canaccord Genuity	Jul 29, 2026	Maintains	Buy	$64.00 → $98.00	44%
Wedbush	Jul 29, 2026	Maintains	Outperform	$72.00 → $99.00	46%
Citigroup	Jul 29, 2026	Maintains	Buy	$60.00 → $100.00	60%
Goldman Sachs	Jul 23, 2026	Maintains	Buy	$60.00 → $75.00	51%
Wells Fargo	Jul 13, 2026	Maintains	Overweight	$57.00 → $74.00	71%
Wedbush	Jun 29, 2026	Maintains	Outperform	$59.00 → $72.00	46%
Canaccord Genuity	Apr 29, 2026	Maintains	Buy	$62.00 → $64.00	44%
Citigroup	Apr 29, 2026	Maintains	Buy	$50.00 → $60.00	60%

The case for and against

Updated Oct 14, 2026

Bull case

Kiniksa Pharmaceuticals is viewed positively because Arcalyst is delivering strong commercial execution, with 1Q26 revenue of $214.3MM, up 56% y/y and 6% q/q, while management lifted FY26 guidance to $930–945MM from $900–920MM. Growth is being supported by more than 4,550 cumulative prescribers, roughly 50% repeat-prescriber contribution, about 20% of patients starting at first recurrence, and only about 18% of the estimated 14,000 multiple-recurrence RP population currently on therapy, leaving substantial runway. The company is also cash flow positive with $468.1MM in cash, and its pipeline—especially KPL-387 with Ph 2 dose-focusing data expected in 2H26 and Ph 3 initiation by YE26—adds long-term upside while extending its IL-1 leadership.

Bear case

Kiniksa Pharmaceuticals is facing a bearish setup because its valuation depends heavily on Arcalyst gaining strong commercial traction in recurrent pericarditis, yet adoption could prove weaker than expected. Its outlook is also challenged by the possibility that competing products emerge with better efficacy or market positioning, which could erode demand and compress its long-term revenue opportunity. In addition, regulatory and commercial uncertainty around whether biologics for rare diseases can sustain premium pricing at commercialization adds another layer of fundamental risk to profitability and valuation.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.